Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes.
NN9388-7782
Phase 1 other active
Quick answer
Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes. for Type 2 diabetes is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Type 2 diabetes
- Phase
- Phase 1
- Modality
- other
- Status
- active